Anixa Biosciences Inc (ANIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has a cash flow conversion efficiency ratio of -0.189x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.61 Million) by net assets ($13.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anixa Biosciences Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Anixa Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Anixa Biosciences Inc (ANIX) financial obligations for a breakdown of total debt and financial obligations.
Anixa Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anixa Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
My Humble House Hospitality Management Consulting Co Ltd
TW:2739
|
0.458x |
|
Sajodongaone Co Ltd
KO:008040
|
0.045x |
|
WooriNet Inc
KQ:115440
|
0.037x |
|
Emeren Group Ltd
NYSE:SOL
|
0.106x |
|
Manali Petrochemicals Limited
NSE:MANALIPETC
|
0.032x |
|
C-Media Electronics
TWO:6237
|
0.005x |
|
Hyosung Chemical Corp
KO:298000
|
-0.068x |
|
Miwon Holdings Co. Ltd
KO:107590
|
0.012x |
Annual Cash Flow Conversion Efficiency for Anixa Biosciences Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Anixa Biosciences Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see Anixa Biosciences Inc (ANIX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $13.95 Million | $-7.17 Million | -0.514x | -32.41% |
| 2024-10-31 | $18.89 Million | $-7.33 Million | -0.388x | -46.17% |
| 2023-10-31 | $23.37 Million | $-6.21 Million | -0.266x | -15.40% |
| 2022-10-31 | $28.20 Million | $-6.49 Million | -0.230x | -62.09% |
| 2021-10-31 | $34.77 Million | $-4.94 Million | -0.142x | +80.99% |
| 2020-10-31 | $8.26 Million | $-6.18 Million | -0.747x | +24.16% |
| 2019-10-31 | $4.81 Million | $-4.74 Million | -0.985x | -19.51% |
| 2018-10-31 | $5.18 Million | $-4.27 Million | -0.824x | -72.04% |
| 2017-10-31 | $7.92 Million | $-3.80 Million | -0.479x | +86.01% |
| 2016-10-31 | $987.48K | $-3.38 Million | -3.425x | -1369.40% |
| 2015-10-31 | $5.05 Million | $1.36 Million | 0.270x | +145.46% |
| 2014-10-31 | $4.01 Million | $-2.38 Million | -0.593x | -161.83% |
| 2013-10-31 | $-3.32 Million | $-3.19 Million | 0.960x | -63.51% |
| 2012-10-31 | $-1.19 Million | $-3.14 Million | 2.630x | +488.68% |
| 2011-10-31 | $1.06 Million | $-716.00K | -0.677x | -29.28% |
| 2010-10-31 | $4.60 Million | $-2.41 Million | -0.523x | +6.83% |
| 2009-10-31 | $4.45 Million | $-2.50 Million | -0.562x | -7.80% |
| 2008-10-31 | $1.73 Million | $-901.87K | -0.521x | +74.09% |
| 2007-10-31 | $1.19 Million | $-2.40 Million | -2.012x | -39.62% |
| 2006-10-31 | $1.28 Million | $-1.85 Million | -1.441x | +6.35% |
| 2005-10-31 | $1.12 Million | $-1.72 Million | -1.539x | -139.14% |
| 2004-10-31 | $1.87 Million | $-1.21 Million | -0.643x | -33.47% |
| 2003-10-31 | $1.99 Million | $-958.50K | -0.482x | -158.94% |
| 2002-10-31 | $2.32 Million | $-431.47K | -0.186x | -8.06% |
| 2001-10-31 | $4.17 Million | $-717.85K | -0.172x | +80.22% |
| 2000-10-31 | $5.56 Million | $-4.84 Million | -0.871x | +10.05% |
| 1999-10-31 | $6.30 Million | $-6.10 Million | -0.968x | -49.64% |
| 1998-10-31 | $11.90 Million | $-7.70 Million | -0.647x | -19.26% |
| 1997-10-31 | $18.80 Million | $-10.20 Million | -0.543x | -194.53% |
| 1996-10-31 | $22.80 Million | $-4.20 Million | -0.184x | +40.29% |
| 1995-10-31 | $9.40 Million | $-2.90 Million | -0.309x | +45.15% |
| 1994-10-31 | $6.40 Million | $-3.60 Million | -0.563x | -77.40% |
| 1993-10-31 | $8.20 Million | $-2.60 Million | -0.317x | +23.53% |
| 1992-10-31 | $4.10 Million | $-1.70 Million | -0.415x | -45.12% |
| 1991-10-31 | $4.20 Million | $-1.20 Million | -0.286x | -6.49% |
| 1990-10-31 | $4.10 Million | $-1.10 Million | -0.268x | -10.00% |
| 1989-10-31 | $4.10 Million | $-1.00 Million | -0.244x | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more